Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Short-term Investments (2022 - 2026)

Compass Therapeutics' Short-term Investments history spans 5 years, with the latest figure at $139.5 million for Q1 2026.

  • On a quarterly basis, Short-term Investments rose 94.89% to $139.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $139.5 million, a 94.89% increase, with the full-year FY2025 number at $178.3 million, up 114.16% from a year prior.
  • Short-term Investments hit $139.5 million in Q1 2026 for Compass Therapeutics, down from $178.3 million in the prior quarter.
  • Over the last five years, Short-term Investments for CMPX hit a ceiling of $178.3 million in Q4 2025 and a floor of $71.6 million in Q1 2025.
  • Historically, Short-term Investments has averaged $128.1 million across 5 years, with a median of $132.9 million in 2023.
  • The widest YoY moves for Short-term Investments: up 114.16% in 2025, down 46.01% in 2025.
  • Tracing CMPX's Short-term Investments over 5 years: stood at $151.7 million in 2022, then decreased by 15.45% to $128.2 million in 2023, then plummeted by 35.09% to $83.2 million in 2024, then surged by 114.16% to $178.3 million in 2025, then decreased by 21.73% to $139.5 million in 2026.
  • Business Quant data shows Short-term Investments for CMPX at $139.5 million in Q1 2026, $178.3 million in Q4 2025, and $173.7 million in Q3 2025.